Clinical Trials Logo

Clinical Trial Summary

We propose to randomize automatic external cardioverter/defibrillators (AECD) in patients who are at high risk for life-threatening abnormal heart rhythms (arrhythmias) and are admitted to the telemetry ward, all other treatments being constant including cardiopulmonary resuscitation.

We hypothesize that the automatic, rapid, accurate and specific diagnostic and therapeutic technology used in AECDs will further increase the rate of survival in patients with cardiac arrest through rapid and automatic defibrillation, independent of operator initiation, as compared to standard cardiopulmonary resuscitation initiated by healthcare providers.


Clinical Trial Description

Cardiac arrest (CA) is defined as the sudden cessation of effective cardiac pumping function as a result of either ventricular asystole (inactivity of the heart) or pulseless ventricular tachycardia/ventricular fibrillation (VT/VF). Pulseless ventricular tachycardia/ventricular fibrillation is an abnormal electrical activity of the ventricles of the heart. Rapid diagnosis and treatment are essential because first, more than a few minutes of total CA results in permanent damage to the brain due to lack of oxygen, and second, the success of resuscitative measures is related to the rapidity with which they are instituted following arrest. For a person in VT/VF the probability of successful defibrillation and subsequent survival to hospital discharge is directly and negatively related to the interval between onset of VT/VF and delivery of first shock.

Comparison: By using AECDs we will evaluate if an automatic, rapid, accurate and specific diagnostic technology will further increase the rate of survival in patients with VT/VF by rapid and automatic defibrillation, independent of operator initiation, as compared to standard cardiopulmonary resuscitation (CPR) with conventional defibrillators initiated by healthcare providers. This trial will be a randomized, controlled trial and will test if AECDs can improve outcome measures when compared to traditional responses.

Conventional defibrillators are manually operated defibrillators that have to be attached to the patient and operated by a healthcare provider or layperson. In contrast, the purpose of AECDs is to automatically detect life-threatening arrhythmias and deliver external shocks according to a programmable prescription for hospitalized patients, who may be at transient risk for the development of life-threatening arrhythmias. AECDs immediately and automatically monitor, detect and treat cardiac arrhythmias with no human intervention. The AECD proposed to be utilized in this trial, PowerHeart CRM, a product of Cardiac Science, Inc, has been evaluated in the hospital setting to assess safety and efficacy, and has been approved by the FDA to be prophylactically attached to hospital patients and provide automatic defibrillation therapy without human intervention.

All patients admitted to the telemetry unit will be asked to volunteer for this study. Up to 3,000 patients will be asked to volunteer in this study during their stay in the telemetry unit. This study will evaluate if there is a way to improve survival in CA by comparing two groups

Group 1: This group includes patients admitted to telemetry unit who will undergo standard measures of CPR in case cardiac arrest is suspected.

Group 2: This group includes patients admitted to telemetry unit who will have an AECD attached to the chest wall and who will also undergo standard measures of CPR in case of cardiac arrest. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00382928
Study type Interventional
Source Atlanta Research and Education Foundation
Contact
Status Completed
Phase Phase 1
Start date October 2006
Completion date September 2009

See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT05791032 - Sub Chronic Evaluation for ATP With an Extravascular Placed ICD Lead (STEP ICD) Study N/A
Completed NCT04011631 - Evaluation of the iD-SystemTM, One-Handed Disposable Internal Defibrillation System. N/A
Active, not recruiting NCT03700125 - Pre-hospital ECMO in Advanced Resuscitation in Patients With Refractory Cardiac Arrest. ( SUB30 ) N/A
Not yet recruiting NCT05325385 - Ventricular Fibrillation Following Out-of-hospital Cardiac Arrest
Completed NCT00241800 - Medications and the Risk of Sudden Cardiac Death N/A
Completed NCT00139542 - AED Use in Out-of-Hospital Cardiac Arrest: A New Algorithm Named "One Shock Per Minute" Phase 3
Completed NCT00119847 - Electrophysiological Effects of Late PCI After MI N/A
Completed NCT00004560 - Public Access Defibrillation (PAD) Community Trial Phase 3
Completed NCT00000531 - Antiarrhythmics Versus Implantable Defibrillators (AVID) Phase 3
Completed NCT00000502 - Evaluation of SC-V Versus Conventional CPR Phase 3
Completed NCT00000492 - Beta-Blocker Heart Attack Trial (BHAT) Phase 3
Completed NCT04080986 - DOuble SEquential External Defibrillation for Refractory VF N/A
Completed NCT01789554 - The Use of Mobile Phones in Out of Hospital Cardiac Arrest to Increase Bystander CPR N/A
Completed NCT01940081 - The Leiden Nonischemic Cardiomyopathy Study
Completed NCT01089634 - Left Ventricular Capture Management Study
Completed NCT01161589 - First Arrhythmia Collection of Transvenous and Simultaneous Subcutaneous Implantable Defibrillator Data N/A
Terminated NCT00776087 - European Health Economic Trial on Home Monitoring in ICD and CRT-D Patients (EuroEco) N/A
Recruiting NCT04576130 - A Danish ICD-study in Patients With Coronary Artery Disease Resuscitated From Ventricular Fibrillation N/A
Withdrawn NCT05236920 - Utility and Procedural Feasibility of REBOA Operationalized for Non-Trauma Application (UP-FRONT) N/A